These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27007227)

  • 21. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response.
    Seaton ED; Szydlo RM; Kanfer E; Apperley JF; Russell-Jones R
    Blood; 2003 Aug; 102(4):1217-23. PubMed ID: 12714516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy.
    Bisaccia E; Palangio M; Gonzalez J; Adler KR; Scarborough R; Goldberg SL; Rowley SD
    J Clin Apher; 2006 Oct; 21(3):181-7. PubMed ID: 16607632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.
    Dignan FL; Aguilar S; Scarisbrick JJ; Shaw BE; Potter MN; Cavenagh J; Apperley JF; Fielding AK; Pagliuca A; Raj K; Marks DI; Peniket A; Crawley C; Koh MB; Child FJ
    Bone Marrow Transplant; 2014 May; 49(5):704-8. PubMed ID: 24566709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunological monitoring of the efficacy of extracorporeal photopheresis for prevention of kidney transplant rejection].
    Faenko AP; Chuksina YY; Zulkarnayev AB; Fedulkina VA; Vatazin AV; Kantaria RO
    Urologiia; 2020 Sep; (4):73-78. PubMed ID: 32897018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant.
    Amat P; López-Corral L; Goterris R; Pérez A; López O; Heras I; Arbona C; Viguria MC; Hernández-Boluda JC; Martínez-Ruiz F; Martínez A; Solano C
    J Clin Apher; 2021 Oct; 36(5):697-710. PubMed ID: 34185332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease.
    Darvay A; Salooja N; Russell-Jones R
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):279-84. PubMed ID: 15096136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.
    Greinix HT; van Besien K; Elmaagacli AH; Hillen U; Grigg A; Knobler R; Parenti D; Reddy V; Theunissen K; Michallet M; Flowers ME;
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1775-82. PubMed ID: 21621629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD.
    González Vicent M; Ramirez M; Sevilla J; Abad L; Díaz MA
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):589-93. PubMed ID: 20962677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
    Malagola M; Cancelli V; Skert C; Leali PF; Ferrari E; Tiburzi A; Sala ML; Donnini I; Chiusolo P; Mussetti A; Battista M; Turra A; Cattina F; Rambaldi B; Schieppati F; Polverelli N; Bernardi S; Perucca S; Marini M; Laszlo D; Savignano C; Patriarca F; Corradini P; Piccirillo N; Sica S; Bosi A; Russo D
    Transplantation; 2016 Dec; 100(12):e147-e155. PubMed ID: 27861297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: A retrospective multicenter study.
    Dal MS; Batgi H; Erkurt MA; Hindilerden IY; Kuku I; Kurtoglu E; Kaya E; Besisik SK; Berber I; Nalcaci M; Ulas T; Altuntas F
    Transfus Apher Sci; 2021 Oct; 60(5):103243. PubMed ID: 34420879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shaping of CD56
    Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2019; 10():547. PubMed ID: 30949182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.
    Foss FM; DiVenuti GM; Chin K; Sprague K; Grodman H; Klein A; Chan G; Stiffler K; Miller KB
    Bone Marrow Transplant; 2005 Jun; 35(12):1187-93. PubMed ID: 15852025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of extracorporeal photopheresis on T cell response in chronic graft-versus-host disease.
    Zhu L; Couriel DR; Chang CH
    Leuk Lymphoma; 2016 Feb; 57(2):376-384. PubMed ID: 26059058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report.
    Berger M; Pessolano R; Albiani R; Asaftei S; Barat V; Carraro F; Biasin E; Madon E; Fagioli F
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):678-87. PubMed ID: 17921848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells.
    Rao V; Saunes M; Jørstad S; Moen T
    Clin Immunol; 2009 Dec; 133(3):303-13. PubMed ID: 19773201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study.
    Sakellari I; Gavriilaki E; Batsis I; Mallouri D; Panteliadou AK; Lazaridou A; Vardi A; Constantinou V; Yannaki E; Papalexandri A; Kaloyannidis P; Smias C; Anagnostopoulos A
    J Clin Apher; 2018 Dec; 33(6):654-660. PubMed ID: 30394564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease.
    Whittle RM; Denney H; Chantry AD; Alfred A; Taylor PC
    J Clin Apher; 2017 Dec; 32(6):462-473. PubMed ID: 28608529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
    Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
    Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymopoiesis, Alterations in Dendritic Cells and Tregs, and Reduced T Cell Activation in Successful Extracorporeal Photopheresis Treatment of GVHD.
    Flinn AM; Ehrlich A; Roberts C; Wang XN; Chou J; Gennery AR
    J Clin Immunol; 2021 Jul; 41(5):1016-1030. PubMed ID: 33651234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection.
    Lorenz K; Rommel K; Mani J; Jin N; Hilgendorf I; Ho AD; Freund M; Schmitt M; Schmitt A
    Leuk Lymphoma; 2015 Mar; 56(3):671-5. PubMed ID: 24913503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.